SCHEMBL3763147

SCHEMBL3763147

CC(=O)c1ccc(N2CCN(CC(=O)N3CCN(C(C)c4ccccc4)CC3)CC2)cc1

nearest known ligand 0.65

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.65
NPSR1 Q6W5P4 1/20 0.65
LMNA P02545 2/20 0.60
GAA P10253 1/20 0.60
ALDH1A1 P00352 5/20 0.60
MAPT P10636 4/20 0.60
KMT2A Q03164 5/20 0.58
MEN1 O00255 3/20 0.55
TP53 P04637 1/20 0.51
KDM4E B2RXH2 1/20 0.49
HTR7 P34969 1/20 0.48
HDAC4 P56524 1/20 0.47
HDAC1 Q13547 1/20 0.47
MAPK1 P28482 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14608971 0.88 PKM (0.66) PKMNPSR1LMNAGAAALDH1A1
SCHEMBL3767673 0.86 ALDH1A1 (0.57) PKMNPSR1LMNAGAAALDH1A1
SCHEMBL3772228 0.84 KMT2A (0.63) PKMNPSR1LMNAGAAALDH1A1
SCHEMBL3769361 0.83 ALDH1A1 (0.53) PKMNPSR1LMNAGAAALDH1A1
SCHEMBL3768396 0.83 ALDH1A1 (0.52) PKMNPSR1LMNAGAAALDH1A1
SCHEMBL3771992 0.82 MAPT (0.57) PKMNPSR1LMNAALDH1A1MAPT
SCHEMBL3762814 0.80 MAPT (0.78) PKMNPSR1LMNAGAAALDH1A1
SCHEMBL3768253 0.77 MAPT (0.72) PKMNPSR1LMNAGAAALDH1A1
SCHEMBL6708152 0.76 CYP2D6 (0.56) LMNAALDH1A1MAPTKMT2AMEN1
SCHEMBL25122016 0.76 PKM (0.60) PKMNPSR1LMNAGAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 PKM 219/4885NPSR1 357/4885LMNA 2902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.